Susquehanna International Group
SNDX icon

Susquehanna International Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Susquehanna International Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.59M Buy
196,621
+178,468
+983% +$3.88M ﹤0.01% 4382
2025
Q4 		$381K Sell
18,153
-16,597
-48% -$290K ﹤0.01% 9410
2025
Q3 		$535K Sell
34,750
-336,713
-91% -$4.41M ﹤0.01% 8784
2025
Q2 		$3.48M Buy
371,463
+41,557
+13% +$457K ﹤0.01% 4673
2025
Q1 		$4.05M Buy
329,906
+202,349
+159% +$2.85M ﹤0.01% 4052
2024
Q4 		$1.69M Sell
127,557
-41,149
-24% -$704K ﹤0.01% 5696
2024
Q3 		$3.25M Buy
168,706
+66,679
+65% +$1.38M ﹤0.01% 4394
2024
Q2 		$2.09M Sell
102,027
-634,121
-86% -$13.3M ﹤0.01% 5015
2024
Q1 		$17.5M Buy
736,148
+711,751
+2,917% +$15.9M ﹤0.01% 1924
2023
Q4 		$527K Sell
24,397
-92,493
-79% -$1.42M ﹤0.01% 8541
2023
Q3 		$1.7M Buy
116,890
+98,220
+526% +$1.86M ﹤0.01% 5470
2023
Q2 		$391K Sell
18,670
-90,655
-83% -$1.89M ﹤0.01% 8887
2023
Q1 		$2.31M Buy
109,325
+88,637
+428% +$2.2M ﹤0.01% 4839
2022
Q4 		$527K Sell
20,688
-35,401
-63% -$826K ﹤0.01% 7723
2022
Q3 		$1.35M Buy
+56,089
New +$1.26M ﹤0.01% 5858
2022
Q2 		– Sell
-115,094
Closed -$1.92M – 13865
2022
Q1 		$2M Buy
115,094
+23,566
+26% +$397K ﹤0.01% 5477
2021
Q4 		$2M Sell
91,528
-242,278
-73% -$4.48M ﹤0.01% 5492
2021
Q3 		$6.38M Buy
333,806
+225,948
+209% +$3.77M ﹤0.01% 3539
2021
Q2 		$1.85M Sell
107,858
-46,976
-30% -$860K ﹤0.01% 6091
2021
Q1 		$3.46M Buy
154,834
+145,684
+1,592% +$3.29M ﹤0.01% 4654
2020
Q4 		$203K Buy
+9,150
New +$190K ﹤0.01% 10015
2020
Q1 		– Sell
-16,129
Closed -$151K – 10830
2019
Q4 		$142K Sell
16,129
-18,932
-54% -$139K ﹤0.01% 8979
2019
Q3 		$262K Buy
+35,061
New +$319K ﹤0.01% 8595
2019
Q1 		– Sell
-64,882
Closed -$370K – 9769
2018
Q4 		$289K Sell
64,882
-33,508
-34% -$184K ﹤0.01% 7076
2018
Q3 		$795K Buy
+98,390
New +$701K ﹤0.01% 5677

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Susquehanna International Group's SNDX Position: Q1 2026 in Review

Susquehanna International Group increased its Syndax Pharmaceuticals (SNDX) stake by 983% in Q1 2026, buying an estimated $3.88M and bringing the position to 196,621 shares worth $4.59M. The position accounts for ﹤0.01% of the portfolio, ranked #4382.

Susquehanna International Group first reported a position in SNDX in Q3 2018 and has held it in 25 quarters since. The position peaked at $17.5M in Q1 2024. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Susquehanna International Group held 196,621 shares of Syndax Pharmaceuticals worth $4.59M as of Q1 2026.
  • Susquehanna International Group bought 178,468 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.88M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4382 holding.
  • Susquehanna International Group first reported a position in Syndax Pharmaceuticals in Q3 2018 and has held it in 25 quarters since.
  • Susquehanna International Group's Syndax Pharmaceuticals position peaked at $17.5M in Q1 2024.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.